Abstract
In different inflammatory diseases, many metalloproteinases are over expressed and thought to promote progression of the disease. Understanding roles of these enzymes in disease progression as well as in normal homeostasis is crucial to identify target enzymes for the disease. Rheumatoid arthritis (RA) is one of the autoimmune inflammatory diseases in which around 1-2 % of the world populations are suffered from. Roles of metalloproteinases are well documented in RA, but so far none of them is proposed to be a target enzyme. However, there are at least three enzymes that can potentially be molecular targets to inhibit progression of RA. Understanding roles of these enzymes in more detail and developing highly selective inhibitors to these enzymes would be essential for novel antimetalloproteinase therapies in future.
Keywords: ADAM, ADAMTS, metalloproteinase, MMP, RA.
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title:Metalloproteinases: potential therapeutic targets for rheumatoid arthritis
Volume: 15 Issue: 3
Author(s): Yoshifumi Itoh
Affiliation:
Keywords: ADAM, ADAMTS, metalloproteinase, MMP, RA.
Abstract: In different inflammatory diseases, many metalloproteinases are over expressed and thought to promote progression of the disease. Understanding roles of these enzymes in disease progression as well as in normal homeostasis is crucial to identify target enzymes for the disease. Rheumatoid arthritis (RA) is one of the autoimmune inflammatory diseases in which around 1-2 % of the world populations are suffered from. Roles of metalloproteinases are well documented in RA, but so far none of them is proposed to be a target enzyme. However, there are at least three enzymes that can potentially be molecular targets to inhibit progression of RA. Understanding roles of these enzymes in more detail and developing highly selective inhibitors to these enzymes would be essential for novel antimetalloproteinase therapies in future.
Export Options
About this article
Cite this article as:
Itoh Yoshifumi, Metalloproteinases: potential therapeutic targets for rheumatoid arthritis, Endocrine, Metabolic & Immune Disorders - Drug Targets 2015; 15 (3) . https://dx.doi.org/10.2174/1871530315666150316122335
DOI https://dx.doi.org/10.2174/1871530315666150316122335 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial [Hot Topic: Progressive and Unconventional Pharmacotherapeutic Approaches to Alzheimers Disease Therapy (Guest Editors: Stuart Maudsley & Wayne Chadwick)]
Current Alzheimer Research NK Cell Receptor and MHC Gene Polymorphisms, Potential Relevance in Malignancies
Current Cancer Therapy Reviews Micro- and Nano-particulate Strategies for Antigen Specific Immune Tolerance to Treat Autoimmune Diseases
Pharmaceutical Nanotechnology Inflammatory and Neurodegenerative Pathways in Depression: A New Avenue for Antidepressant Development?
Current Medicinal Chemistry Molecular Targets in Osteoarthritis: Metalloproteinases and Their Inhibitors
Current Drug Targets DNA Methylation, Chondrogenesis, and Cartilage Degeneration
Current Rheumatology Reviews The Forkhead Transcription Factor FOXO3a Controls Microglial Inflammatory Activation and Eventual Apoptotic Injury through Caspase 3
Current Neurovascular Research RAGE: A Multi-Ligand Receptor Unveiling Novel Insights in Health and Disease
Current Medicinal Chemistry MicroRNAs as Modulators of the Platelet Proteome
Current Proteomics Development and Production of Commercial Therapeutic Monoclonal Antibodies in Mammalian Cell Expression Systems: An Overview of the Current Upstream Technologies
Current Pharmaceutical Biotechnology Anticancer Antifolates: Current Status and Future Directions
Current Pharmaceutical Design Neuropsychiatric Systemic Lupus Erythematosus
Current Neuropharmacology Editorial [ The Wide Roles of Cytokines During Evolution Executive Editors: M. de Eguileor and E. Ottaviani ]
Current Pharmaceutical Design Preface (Hot Topic: New Frontiers and ”Pitfalls“ in Cytokine and Anti-cytokine Therapies Executive Editor: Atsushi Oda)
Current Pharmaceutical Design Current Status of SUMOylation Inhibitors
Current Medicinal Chemistry Subject Index To Volume 12
Current Pharmaceutical Design Effects of Hypoxia and Ischemia on MicroRNAs in the Brain
Current Medicinal Chemistry The Possibilities and Pitfalls for Anti-Complement Therapies in Inflammatory Diseases
Current Drug Targets - Inflammation & Allergy Medical and Dental Implications of Down Syndrome: A Review Part 1: General and Craniofacial Characteristic
Applied Clinical Research, Clinical Trials and Regulatory Affairs Preparation of 2-(4-{[4-(Quinolin-2-ylmethoxy)phenyl]sulfanyl}phenyl) Propionic Acid (VUFB 20615) and 2-Methyl-2-(4-{[4-(quinolin-2- ylmethoxy)Phenyl]sulfanyl}phenyl)Propionic Acid (VUFB 20623) as Potential Antileukotrienic Agents
Current Organic Chemistry